<div id="readability-page-1"><p>Evergreen Capital Management LLC decreased its position in shares of  Eli Lilly and Company (NYSE:LLY - Free Report) by 8.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 10,288 shares of the company's stock after selling 968 shares during the quarter. Evergreen Capital Management LLC's holdings in Eli Lilly and Company were worth $7,942,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>Which Healthcare Stock Is the Best Buy Right Now?</li></ul><p>Several other institutional investors and hedge funds also recently made changes to their positions in the company. Highline Wealth Partners LLC increased its holdings in shares of  Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after purchasing an additional 20 shares in the last quarter.  FPC Investment Advisory Inc. increased its holdings in  Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after buying an additional 43 shares in the last quarter.  Prudent Man Investment Management Inc. purchased a new position in  Eli Lilly and Company in the 4th quarter worth about $48,000.  Compass Financial Services Inc bought a new position in  Eli Lilly and Company during the 4th quarter valued at about $50,000.  Finally, Fiduciary Advisors Inc. purchased a new stake in shares of  Eli Lilly and Company during the 4th quarter valued at about $58,000. Institutional investors own  82.53% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>LLY has been the topic of a number of research analyst reports. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lowered their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Leerink Partners  set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. Morgan Stanley cut their price objective on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, April 9th. Wells Fargo &amp; Company increased their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, March 5th. Finally, StockNews.com raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued  a buy rating to the company. Based on data from MarketBeat, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $1,012.00.</p><ul><li>Price Targets Show These 3 Stocks Near the $1 Trillion Mark</li></ul><p><b>Read Our Latest Report on Eli Lilly and Company</b></p><h2>Eli Lilly and Company Stock Performance</h2><p>Shares of NYSE LLY opened at $756.55 on Wednesday. The company has a market cap of $717.34 billion, a P/E ratio of 64.61, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm's fifty day moving average is $832.96 and its two-hundred day moving average is $821.54. </p><ul><li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li></ul><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%.  As a group, analysts anticipate that  Eli Lilly and Company will post 23.48 EPS for the current fiscal year. </p><h2>Insider Buying and Selling</h2><p>In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by company insiders. </p><h2>Eli Lilly and Company Company Profile</h2> (Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>See Also</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>What Are Dividend Contenders? Investing in Dividend Contenders</li><li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li><li>What is a Stock Market Index and How Do You Use Them?</li><li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li><li>Pros And Cons Of Monthly Dividend Stocks</li><li>Congress! Who Traded What During the Tariff-Induced Meltdown </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Evergreen Capital Management LLC reduced its stake in Eli Lilly and Company (NYSE: LLY) by 8.6%, selling 968 shares during the fourth quarter, leaving it with 10,288 shares valued at approximately $7.94 million. Other institutional investors also adjusted their positions, with notable increases from Highline Wealth Partners LLC and FPC Investment Advisory Inc. Analysts have upgraded Eli Lilly's stock ratings, with a consensus rating of "Moderate Buy" and a price target of $1,012.00. The stock opened at $756.55, with a market cap of $717.34 billion and a P/E ratio of 64.61.</p>

Evergreen Capital Management LLC Sells 968 Shares of Eli Lilly and Company (NYSE:LLY)